Cytokinetics, Incorporated
CYTK
Κατάταξη σε μετοχές
#2308
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Τιμή μετοχής
$62.08
Κεφαλαιοποίηση
$8.63B
Αλλαγή (1 ημέρα)
0.21%
Αλλαγή (1 έτος)
6.23%
Χώρα
US
Εμπόριο Cytokinetics, Incorporated (CYTK)
Κατηγορία
Healthcare
EPS για Cytokinetics, Incorporated (CYTK)
EPS στις June 2026 TTM: $-7.21
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Cytokinetics, Incorporated, το τρέχον EPS της εταιρείας (TTM) είναι $-7.21. Στο τέλος του 2023, η εταιρεία είχε EPS $-5.45, αύξηση σε σχέση με το EPS του 2022 που ήταν $-4.33.
Ιστορικό EPS της Cytokinetics, Incorporated από 2000 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-7.21 | 37.07% |
| 2024 | $-5.26 | -3.49% |
| 2023 | $-5.45 | 25.87% |
| 2022 | $-4.33 | 54.64% |
| 2021 | $-2.80 | 42.13% |
| 2020 | $-1.97 | -23.94% |
| 2019 | $-2.59 | 32.82% |
| 2018 | $-1.95 | -24.71% |
| 2017 | $-2.59 | -731.71% |
| 2016 | $0.41 | -142.27% |
| 2015 | $-0.97 | 136.59% |
| 2014 | $-0.41 | -66.94% |
| 2013 | $-1.24 | -42.33% |
| 2012 | $-2.15 | -47.04% |
| 2011 | $-4.06 | -11.93% |
| 2010 | $-4.61 | -278.68% |
| 2009 | $2.58 | -137.66% |
| 2008 | $-6.85 | 11.20% |
| 2007 | $-6.16 | -34.19% |
| 2006 | $-9.36 | 5.52% |
| 2005 | $-8.87 | -21.37% |
| 2004 | $-11.28 | -89.01% |
| 2003 | $-102.62 | 29.10% |
| 2002 | $-79.49 | 18.50% |
| 2001 | $-67.08 | -17.49% |
| 2000 | $-81.30 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | -340.22% |
US
|
|
| $-7.98 | 10.68% |
US
|
|
| $-5.29 | -26.63% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -484.74% |
NL
|
